Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

 

Press Releases

5 July 2022

Statement on Patent Infringement Lawsuit in Germany

29 June 2022

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Addi..

25 June 2022

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demons..

Press releases (more)

Upcoming Events

August 8, 2022 at 8:00 AM EDT

August 8, 2022: Second Quarter 2022 Earnings

November 7, 2022 at 8:00 AM EST

November 7, 2022: Third Quarter 2022 Earnings

Upcoming events (more)

Stock Quote

Jul 7, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.